Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Deals

Koutech Robotics Secures Series A Funding for Surgical Innovation

Fineline Cube Sep 21, 2022

China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has...

Company Drug

CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit

Fineline Cube Sep 21, 2022

China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...

Company Deals

Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...

Company

Northeast Pharmaceutical to Invest in Shanghai Subsidiary for ADC and CAR-T Development

Fineline Cube Sep 21, 2022

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced plans to invest RMB 500 million...

Policy / Regulatory

Beijing Designates 923 Medical Entities for National Reimbursement Drug List

Fineline Cube Sep 21, 2022

The Beijing Municipal Medical Insurance Bureau has released a notification indicating that a total of...

Company

Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift

Fineline Cube Sep 20, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report,...

Company Drug

Junshi Biosciences’ Tuoyi Approved for First-Line NSCLC Treatment in China

Fineline Cube Sep 20, 2022

China’s Center for Drug Evaluation (CDE) has approved Junshi Biosciences’ (HKG: 1877, SHA: 688180) Tuoyi...

Company Drug

Sun-Novo’s STC007 Gains NMPA Approval for Postoperative Pain Study

Fineline Cube Sep 20, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from...

Company Deals

WuXi Biologics Partners with Elpiscience for Macromolecule Development

Fineline Cube Sep 20, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...

Company Drug

Tasly Pharmaceuticals Gains NMPA Approval for B1344 Diabetes Study

Fineline Cube Sep 20, 2022

China-based Tasly Pharmaceuticals (SHA: 600535) has announced that it has received approval from the National...

Company Drug

Clover Biopharmaceuticals Reports Positive Phase III Data for COVID-19 Vaccine SCB-2019

Fineline Cube Sep 20, 2022

China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced additional positive Phase III clinical trial data...

Company Drug

RemeGen Announces Positive Phase III Results for Telitacicept in SLE

Fineline Cube Sep 20, 2022

China-based pharma firm RemeGen (HKG: 9995) has announced the conclusion of a Phase III confirmatory...

Company Drug

BeiGene’s Brukinsa Receives New EU and UK Indications for BTK Inhibitor

Fineline Cube Sep 20, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has received two new indication...

Company Drug

Alphamab Oncology Doses First Patient in Phase I Study for JSKN003 in Australia

Fineline Cube Sep 20, 2022

Alphamab Oncology (HKG: 9966) has announced that the first patient has been dosed in a...

Company Deals Hospital

Beijing Launches HIV Precision Medicine Standardization Project

Fineline Cube Sep 20, 2022

On September 17, an HIV precision medicine standardization project was initiated in Beijing. The project,...

Company Deals

Fosun Pharma Signs Exclusive Licensing Deal for H008 with Carephar

Fineline Cube Sep 20, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has signed an exclusive...

Company Deals

Suzhou Weiyou Gene Bio Raises Pre-Series A Funding for Gene Therapy Pipeline

Fineline Cube Sep 20, 2022

China-based Suzhou View Gene Biotechnology Co., Ltd has reportedly raised “tens of millions” of renminbi...

Company Medical Device

Lepu Medtech Receives Approval for Innovative Peripheral Cutting Balloon

Fineline Cube Sep 19, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Company Deals

Lepu Medtech Prices GDR Offering for International Expansion

Fineline Cube Sep 19, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has priced...

Company Deals

Zhong’ao Biopharmaceutical Secures Series A Funding for Cancer and HPV-Related Disease R&D

Fineline Cube Sep 19, 2022

China-based Zhong’ao Biopharmaceutical Technology (Guangdong) Co., Ltd. has reportedly raised an undisclosed amount of money...

Posts pagination

1 … 570 571 572 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.